Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer

Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer is a phase 3, randomised interventional study registered as NCT07528209 by Sun Yat-sen University, with a registry enrolment figure of 556 participants, started 2026-04-20 and due to reach its primary completion in 2032-04-20. Interventions recorded: Pucotenlimab combine with CAPOX; CAPOX. Conditions listed: Rectal Cancer; pMMR (Microsatellite Stable Rectal Cancer). Primary outcome: 3-year disease-free survival (DFS) rate. Colorectal eligibility wording from the registry: "Histologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.